Tania Deis , Benedicte Heegaard , Kasper Rossing , Berit Philbert , Michael Vinther , Niels Risum , Peter Karl Jacobsen , Jens P. Goetze , Finn Gustafsson
{"title":"Transcardiac gradients of pro-cholecystokinin, cholecystokinin, and gastrin in patients with and without heart failure with reduced ejection fraction","authors":"Tania Deis , Benedicte Heegaard , Kasper Rossing , Berit Philbert , Michael Vinther , Niels Risum , Peter Karl Jacobsen , Jens P. Goetze , Finn Gustafsson","doi":"10.1016/j.peptides.2025.171353","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cholecystokinin (CCK) is secreted from the intestines in response to food intake. We previously reported that the CCK gene is also expressed in the mammalian heart, and it has been hypothesized that proCCK could be a novel cardiac biomarker. However, it is not known whether cardiac gene expression leads to secretion in humans.</div></div><div><h3>Purpose</h3><div>To investigate myocardial secretion of proCCK in patients with heart failure with reduced ejection fraction (HFrEF) or arrythmias.</div></div><div><h3>Methods</h3><div>A total of 115 patients undergoing invasive cardiac procedures were included: 55 with HFrEF (67 years [interquartile range (IQR) 60–76], 72.7 % male, LVEF 30 % [IQR 20–35]), and 60 without HFrEF (26 with Wolff-Parkinson-White syndrome (WPW) (30 years [IQR 26–39], 61.5 % male), and 34 with atrial fibrillation (AFIB) (66 years [IQR 60–71], 61.8 % male)). Blood was collected from the coronary sinus (CS) as well as the left atrium or femoral artery (A) to determine the transcardiac concentration gradient (TC<sub>proCCK</sub>) (CS proCCK concentration - A proCCK concentration). Radioimmunoassays were used for measurements of plasma hormones.</div></div><div><h3>Results</h3><div>TC<sub>proCCK</sub> across failing hearts was 0.05 pmol/l (IQR: −1.49–2.67) (<em>p = 0.365</em>). In non-failing hearts, TC<sub>proCCK</sub> was 0.35 pmol/l (IQR: −1.57–1.29) (<em>p = 0.778</em>) for WPW and 0.68 pmol/l (IQR: −1.58–3.28) (<em>p = 0.133</em>) for AFIB. Transcardiac gradients for N-terminal pro B-type natriuretic peptide (NT-proBNP) were observed in all groups.</div></div><div><h3>Conclusions</h3><div>No evidence of net myocardial secretion of proCCK was found in either failing or structurally normal hearts, questioning its proposed role as a cardiac biomarker.</div></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"184 ","pages":"Article 171353"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptides","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196978125000142","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Cholecystokinin (CCK) is secreted from the intestines in response to food intake. We previously reported that the CCK gene is also expressed in the mammalian heart, and it has been hypothesized that proCCK could be a novel cardiac biomarker. However, it is not known whether cardiac gene expression leads to secretion in humans.
Purpose
To investigate myocardial secretion of proCCK in patients with heart failure with reduced ejection fraction (HFrEF) or arrythmias.
Methods
A total of 115 patients undergoing invasive cardiac procedures were included: 55 with HFrEF (67 years [interquartile range (IQR) 60–76], 72.7 % male, LVEF 30 % [IQR 20–35]), and 60 without HFrEF (26 with Wolff-Parkinson-White syndrome (WPW) (30 years [IQR 26–39], 61.5 % male), and 34 with atrial fibrillation (AFIB) (66 years [IQR 60–71], 61.8 % male)). Blood was collected from the coronary sinus (CS) as well as the left atrium or femoral artery (A) to determine the transcardiac concentration gradient (TCproCCK) (CS proCCK concentration - A proCCK concentration). Radioimmunoassays were used for measurements of plasma hormones.
Results
TCproCCK across failing hearts was 0.05 pmol/l (IQR: −1.49–2.67) (p = 0.365). In non-failing hearts, TCproCCK was 0.35 pmol/l (IQR: −1.57–1.29) (p = 0.778) for WPW and 0.68 pmol/l (IQR: −1.58–3.28) (p = 0.133) for AFIB. Transcardiac gradients for N-terminal pro B-type natriuretic peptide (NT-proBNP) were observed in all groups.
Conclusions
No evidence of net myocardial secretion of proCCK was found in either failing or structurally normal hearts, questioning its proposed role as a cardiac biomarker.
期刊介绍:
Peptides is an international journal presenting original contributions on the biochemistry, physiology and pharmacology of biological active peptides, as well as their functions that relate to gastroenterology, endocrinology, and behavioral effects.
Peptides emphasizes all aspects of high profile peptide research in mammals and non-mammalian vertebrates. Special consideration can be given to plants and invertebrates. Submission of articles with clinical relevance is particularly encouraged.